Trials / Unknown
UnknownNCT02836639
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Phase II Study for Safety and Efficacy of BEB (Bendamustine, Etoposide, Busulfan) Conditioning Regimen for ASCT in Non-Hodgkin's Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Pusan National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Phase II study for safety and efficacy of BEB (Bendamustine, Etoposide, Busulfan) conditioning regimen for ASCT in non-Hodgkin's lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Busulfan | Busulfan 0.8 mg/kg four times per day from day -7 to day -5 |
| DRUG | Etoposide | Etoposide 400 mg/m2 from day -5 to day -4 |
| DRUG | Bendamustine | Bendamustine 200 mg/m2 starting dose on day -3 and -2 |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-12-01
- First posted
- 2016-07-19
- Last updated
- 2016-07-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02836639. Inclusion in this directory is not an endorsement.